Skip to main content
SpringerLink
Log in

Controversy and Consensus on the Management of Patients With Pseudomyxoma Peritonei

  • Lower Gastrointestinal Cancers (AB Benson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Pseudomyxoma peritonei and peritoneal carcinomatosis derived from appendiceal epithelial tumors are controversial entities from classification to treatment. For the former entity, multiple classification systems have been attempted to distinguish indolent from more aggressive subtypes. The treatment of the low grade variants is managed with serial cytoreduction surgery, with data indicating possible, but unproven, benefit from heated intraperitoneal chemotherapy (HIPEC). There is no consensus on the role of cytoreduction and HIPEC for the management of the more aggressive histologic variants and peritoneal carcinomatosis. Currently, we believe systemic chemotherapy is the standard of care for patients with the high grade variants and peritoneal carcinomatosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Werth R. Klinische und anatomische untersuchungen zur lehre von den bauchgeschwullsten und der laparotomie. Arch Gynecol. 1884;24:100–18.

    Google Scholar 

  2. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104–9. Epub 2007/01/02.

    Article  PubMed  Google Scholar 

  3. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2008;34(2):196–201. Epub 2007/05/26.

    Article  CAS  Google Scholar 

  4. McDonald JR, O'Dwyer ST, Rout S, Chakrabarty B, Sikand K, Fulford PE, et al. Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. Br J Surg. 2012;99(7):987–92. Epub 2012/04/21.

    Article  PubMed  CAS  Google Scholar 

  5. Mann Jr WJ, Wagner J, Chumas J, Chalas E. The management of pseudomyxoma peritonei. Cancer. 1990;66(7):1636–40. Epub 1990/10/01.

    Article  PubMed  Google Scholar 

  6. Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134(6):864–70. Epub 2010/06/09.

    PubMed  Google Scholar 

  7. Nakakura EK. Pseudomyxoma peritonei: more questions than answers. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(20):2429–30. Epub 2012/05/23.

    Article  Google Scholar 

  8. Panarelli NC, Yantiss RK. Mucinous neoplasms of the appendix and peritoneum. Arch Pathol Lab Med. 2011;135(10):1261–8. Epub 2011/10/06.

    Article  PubMed  Google Scholar 

  9. Carr NJ, Finch J, Ilesley IC, Chandrakumaran K, Mohamed F, Mirnezami A, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 2012;65(10):919–23. Epub 2012/06/22. Experience of 274 patients PMP categorized as low or high grade, with significant impact on prognosis.

    Google Scholar 

  10. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089–103. Epub 2003/07/29.

    Article  PubMed  Google Scholar 

  11. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol. 1995;19(12):1390–408.

    Article  PubMed  CAS  Google Scholar 

  12. Bradley RF, Stewart IV JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30(5):551–9. Epub 2006/05/16.

    Article  PubMed  Google Scholar 

  13. Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer. 1995;75(3):757–68.

    Article  PubMed  CAS  Google Scholar 

  14. Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol. 2005;12(6):291–311. Epub 2005/12/07.

    Article  PubMed  Google Scholar 

  15. Carr NJSL. Adenocarcinoma of the appendix. In: Bosman FTCF, Hruban RH, editors. WHO Classification of Tumors of the Digestive System. Lyon: IARC; 2010.

    Google Scholar 

  16. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92(1):85–91. Epub 2001/07/10.

    Article  PubMed  CAS  Google Scholar 

  17. Guo AT, Li YM, Wei LX. Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors. World J Gastroenterol. 2012;18(24):3081–8. Epub 2012/07/14.

    Article  PubMed  Google Scholar 

  18. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(20):2449–56. Epub 2012/05/23. Largest retrospective experience with PMP and CRS/HIPEC detailing long-term survival.

    Google Scholar 

  19. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? The lancet oncology. 2012;13(8):e362–9. Epub 2012/08/01. This paper addresses the controversies surrounding cytoreductive surgery and HIPEC in the management of peritoneal carcinomatosis.

  20. Esquivel J, Sugarbaker PH. Clinical presentation of the Pseudomyxoma peritonei syndrome. Br J Surg. 2000;87(10):1414–8. Epub 2000/10/24.

    Article  PubMed  CAS  Google Scholar 

  21. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219(2):112–9. Epub 1994/02/01.

    Article  PubMed  CAS  Google Scholar 

  22. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241(2):300–8. Epub 2005/01/15.

    Article  PubMed  Google Scholar 

  23. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg. 1989;32(3):164–70. Epub 1989/05/01.

    PubMed  CAS  Google Scholar 

  24. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727–31. Epub 2000/01/06.

    Article  PubMed  CAS  Google Scholar 

  25. McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res. 2013. Epub 2013/03/16. Meta-analysis of 15 studies analyzing survival associated with combined cytoreductive surgery and intraperitoneal chemotherapy.

  26. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98(4):277–82. Epub 2008/08/30.

    Article  PubMed  Google Scholar 

  27. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69–76. Epub 2006/01/04.

    Article  PubMed  Google Scholar 

  28. Canbay E, Ishibashi H, Sako S, Mizumoto A, Hirano M, Ichinose M, et al. Preoperative Carcinoembryonic Antigen Level Predicts Prognosis in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. World J Surg. 2013. Epub 2013/03/08.

  29. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14(8):2300–8. Epub 2007/05/19.

    Article  PubMed  Google Scholar 

  30. Shetty S, Thomas P, Ramanan B, Sharma P, Govindarajan V, Loggie B. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J Surg Res. 2013;180(1):97–103. Epub 2012/12/04.

    Article  PubMed  CAS  Google Scholar 

  31. Andreasson H, Wanders A, Sun XF, Willen R, Graf W, Nygren P, et al. Histopathological classification of pseudomyxoma peritonei and the prognostic importance of PINCH protein. Anticancer Res. 2012;32(4):1443–8. Epub 2012/04/12.

    PubMed  Google Scholar 

  32. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(3):263–7. Epub 2011/12/14. Outcomes of patients with peritoneal carcinomatosis of colorectal origin from two randomized trials, demonstrating inferior outcomes relative to metastatic colorectal cancer without peritoneal carcinomatosis.

    Google Scholar 

  33. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(24):4011–9. Epub 2006/08/22.

    Article  Google Scholar 

  34. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(20):3737–43. Epub 2003/10/11.

    Article  Google Scholar 

  35. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. Epub 2008/06/04.

    Article  PubMed  Google Scholar 

  36. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608–18. Epub 2010/08/26.

    Article  PubMed  Google Scholar 

  37. Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11(5):518–21. Epub 2004/05/05.

    Article  PubMed  Google Scholar 

  38. National Comprehensive Cancer Network. NCCN Guidelines Colon Cancer, Version 3.2013. .

Download references

Conflicts of Interest

Jason E. Faris declares that he has no conflicts of interest.

David P. Ryan declares that he has no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Massachusetts General Hospital Cancer Center, Yawkey 7E 55 Fruit Street, Boston, MA, 02114, USA

    Jason E. Faris MD & David P. Ryan MD

Authors
  1. Jason E. Faris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Ryan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P. Ryan MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faris, J.E., Ryan, D.P. Controversy and Consensus on the Management of Patients With Pseudomyxoma Peritonei. Curr. Treat. Options in Oncol. 14, 365–373 (2013). https://doi.org/10.1007/s11864-013-0240-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-013-0240-x

Keywords

Search

Navigation